GSK Launches Hostile Takeover Bid for Human Genome Sciences

May 9, 2012

May 10, 2012 | GlaxoSmithKline has launched a hostile takeover bid for long-time partner Human Genome Sciences worth $2.6 billion, or $13/share. A poll of analysts revealed that they expected sale price will be around $15/share. The board of Human Genome turned down a bid from GSK last month. Baltimore Sun